European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem

Europe accounts for just 7% of global life sciences Venture Capital (VC), and 66 of 67 EU biotech IPOs in the past six years have been listed outside the EU. Europe is failing to scale life science innovation, held back by fragmented capital markets and structural investment barriers. Reason enough for a group of leading VC firms, such as Forbion and Sofinnova Partners, together with research institutions and sector stakeholders, to launch the European Life Sciences Coalition (ELSC) in association with Invest Europe. The coalition collectively manages more than €24 billion in life sciences assets and supports over 1400 companies. Its goal is to mobilise significantly more private and public investment, improve capital deployment, and create a more integrated environment for scaling European biotech. Ultimately, the ELSC aims to ensure that Europe can finance, grow, and retain its scientific and commercial breakthroughs, securing a strong global position in biotech.